Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK/PD and QT Study of HRS-5965 in Healthy Subjects
NCT06684041Phase 1Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-5965 in Hemolytic anemia (HA) (3 arms), sponsored by Chengdu Suncadia Pharmaceuticals. Primary endpoints: Incidence of subjects with adverse events at 7 days and Baseline and placebo-adjusted QTcF at 24 hours. Started Nov 2024; status: completed.
02
Drugs
HRS-5965
03
Conditions
Hemolytic anemia (HA)
Beyond the preview
Go deeper on NCT06684041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684041.